Vertex Reports First Quarter 2024 Financial Results
Vertex Pharmaceuticals Incorporated, a global biotechnology company investing in scientific innovation to create transformative medicines for people with serious diseases, has announced important advancements across its suzetrigine pain programme, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain